Recent advances in antitumor antibiotics.
An effective treatment schedule with bleomycin in combination with mitomycin and a new effective area in treatment with neocarzinostatin was introduced. Studies on more useful derivatives or analogues of bleomycin and anthracycline antitumor antibiotics were described. Bleomycin PEP thus selected may become a useful agent. Aclacinomycin and various other anthracycline glycosides were isolated from beer fermentation and tested. Future progress in microbiol secondary metabolites useful in cancer treatment was discussed.
D015250:Aclarubicin / Q000031:analogs & derivatives; D000818:Animals; D000880:Anthraquinones / Q000378:metabolism / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000378:metabolism / Q000627:therapeutic use*; D001761:Bleomycin / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D004247:DNA / Q000378:metabolism; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006027:Glycosides / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D013329:Structure-Activity Relationship; D009353:Zinostatin / Q000627:therapeutic use
D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D006027:Glycosides; C011157:aclacinomycins; D001761:Bleomycin; D015250:Aclarubicin; D004247:DNA; D009353:Zinostatin; D003630:Daunorubicin